Welcome to Xention

Xention is developing novel therapies for the treatment of atrial fibrillation using its proprietary platform of ion channel drug discovery and development.

The Company is developing drug candidates that modulate two novel, but well characterised, ion channels and expects to develop breakthrough products in this area of huge unmet medical need.

In addition, we have established alliances with major pharmaceutical companies in areas outside our core interests.

Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug

20 March 2012

XEN-D0103, a potent and selective Kv1.5 antagonist, is safe and well tolerated in healthy volunteers
Read More

Xention Initiates Human Clinical Testing of New Atrial Fibrillation Drug

27 July 2011

XEN-D0103, a potent and selective Kv1.5 antagonist, commences single and multiple ascending dose study
Read More

Xention to Present on the Role of Ion Channels in Atrial Fibrillation

29 June 2011

Dr David Madge to present status of Xention Atrial Fibrillation research
Read More